Immutep Ltd.
http://www.immutep.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immutep Ltd.
Tech Transfer Roundup: MD Anderson Working To Unlock Promise Of Tumor-Infiltrating Lymphocytes
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.
Centessa ‘Creates Pharma Pipeline Overnight’ Using Novel R&D Approach
With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.
Centessa Looks To Transform Drug Development With ‘Asset Centric’ Model
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Immutep S.A.S.
- Immutep GmbH
- Immutep, U.S., Inc.
- Prima BioMed Ltd.